Changes in Brain pH Associated with Range of Cognitive Disorders

Given the complexity and depth of the research findings from the study published in eLife today, "Large-scale Animal Model Study Uncovers Altered Brain pH and Lactate Levels as a Transdiagnostic Endophenotype of Neuropsychiatric Disorders Involving Cognitive Impairment," a comprehensive exploration is necessary to fully appreciate its impact and implications, particularly in the context of cognitive impairments across a spectrum of neuropsychiatric disorders.

The research, conducted by an international consortium led by Dr. Hideo Hagihara and Professor Tsuyoshi Miyakawa, involves 131 researchers and spans 105 laboratories in seven countries. This collaborative effort underscores the universal relevance and critical nature of understanding brain energy metabolism dysfunction in cognitive disorders.

Introduction to the Study

This groundbreaking study, emerges from the collaborative efforts of the International Brain pH Project Consortium. The research focuses on exploring the transdiagnostic endophenotype involving energy metabolism dysfunction, notably altered brain pH and lactate levels, across various animal models of neuropsychiatric and neurodegenerative disorders, including schizophrenia, autism spectrum disorders, bipolar disorder, depressive disorders, and Alzheimer's disease. The discovery of a common endophenotype suggests that these metabolic alterations are intrinsic characteristics of the disorders rather than the effects of medication, offering new pathways for understanding and treating cognitive impairments.

Key Findings

The study meticulously examined 109 strains/conditions of mice, rats, and chicks, revealing that approximately 30% exhibited significant changes in brain pH and lactate levels, suggesting widespread energy metabolism dysfunction in the brain across different neuropsychiatric conditions. These alterations were linked to impaired working memory, directly impacting cognitive function.

Furthermore, the research indicated variability in the metabolic patterns within autism models, suggesting the existence of subpopulations within the autism spectrum with distinct metabolic dysfunctions. Confirming these findings in an independent cohort of animal models reinforces the association between higher brain lactate levels and poor working memory performance.

Implications for Treatment and Future Research

Identifying altered brain energy metabolism as a transdiagnostic endophenotype opens up innovative avenues for treatment strategies that target these shared metabolic dysfunctions. The research lays the groundwork for developing transdiagnostic characterizations of disorders involving cognitive impairment, potentially leading to tailored treatments for patient subgroups characterized by specific alterations in brain energy metabolism.

The study also highlights the need for further research to understand the mechanistic insights into the reduction in pH and the increase in lactate levels. While the increase in lactate production in response to neural hyperactivity is within the study proposed as a potential underlying reason, future studies are crucial for uncovering effective treatment strategies across diverse animal models with brain pH changes.

Conclusion

The study by Dr. Hideo Hagihara, Professor Tsuyoshi Miyakawa, and the International Brain pH Project Consortium marks a significant advance in neuroscience and neurology. By unveiling a common endophenotype across a range of neuropsychiatric and neurodegenerative disorders, this research paves the way for new understanding and therapeutic approaches targeting the intricate relationship between brain energy metabolism dysfunction and cognitive impairments.

The collaborative nature of this research, encompassing a wide range of disorders and models, underscores the importance of international cooperation in addressing the complex challenges of neuropsychiatric research.

This comprehensive exploration of the study, encompassing its key findings, implications, and future directions, offers a detailed insight into the potential of altered brain pH and lactate levels as biomarkers for cognitive impairments across neuropsychiatric disorders.

The work of Dr. Hagihara, Professor Miyakawa, and their colleagues represents a significant step forward in understanding and treating cognitive dysfunctions. It ultimately contributes to developing more effective, targeted treatments for those affected by these conditions.

© Mike Robinson, Founder Global Cannabinoid Researcher Center and Creator of ECS Balance Control, The Researcher OG

References:

Hideo Hagihara, Hirotaka Shoji, et al (2024) Large-scale animal model study uncovers altered brain pH and lactate levels as a transdiagnostic endophenotype of neuropsychiatric disorders involving cognitive impairment eLife 12:RP89376 https://doi.org/10.754/eLife.89376.3